# EDGAR Filing Document

**Accession Number:** 0000725363
**File Stem:** 0000000000-25-008023
**Filing Date:** 2025-7
**Character Count:** 2407
**Document Hash:** e73356eefef74db352c2f2fc6e4b0544
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008023.hdr.sgml**: 20260610

**ACCESSION NUMBER**: 0000000000-25-008023

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250730

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CEL SCI CORP
- **CENTRAL INDEX KEY:** 0000725363
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 840916344
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08253

**BUSINESS ADDRESS:**
- **STREET 1:** 8229 BOONE BLVD .
- **STREET 2:** SUITE 802
- **CITY:** VIENNA
- **STATE:** VA
- **ZIP:** 22182
- **BUSINESS PHONE:** 7035069460

**MAIL ADDRESS:**
- **STREET 1:** 8229 BOONE BLVD.
- **STREET 2:** SUITE 802
- **CITY:** VIENNA
- **STATE:** VA
- **ZIP:** 22182

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERLEUKIN 2 INC
- **DATE OF NAME CHANGE:** 19880317
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001654954-25-008465

## Text-Extract

```

                                                            July 30, 2025

Geert Kersten
Chief Executive Officer
Cel-Sci Corporation
8229 Boone Blvd. #802
Vienna, VA 22182

       Re: Cel-Sci Corporation
           Draft Registration Statement on Form S-1
           Submitted July 25, 2025
           CIK No. 0000725363
Dear Geert Kersten:

       This is to advise you that we do not intend to review your registration
statement.

       We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

       Please contact Doris Stacey Gama at 202-551-3188 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   William Hart, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._